Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]
Clinical Trials
Cordis shares positive study results from multiple drug-eluting balloon studies
Cordis announced new data from two major peripheral studies evaluating its Selution SLR drug-eluting balloon. The Miami Lakes, Florida-based company presented 12-month results from the SUCCESS PTA study at the Charing Cross Symposium in London. It then shared SELUTION SFA Japan three-year results today at the Japan Endovascular Treatment Conference in Osaka. According to Cordis, the studies […]
Data backs Boston Scientific drug-eluting stent
Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]
R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study
R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]
Study says smart infusion pump interoperability can enhance medication delivery
A review of several studies highlighted the role smart infusion pump interoperability can play in medication administration. According to the study’s abstract, medication administration issues remain a persistent issue in the U.S. Investigators believe that smart infusion pump interoperability with electronic health records (EHRs) could potentially reduce IV errors. Smart infusion pumps safely deliver IV medications […]
Aptar reports positive adherence results with iPump dose software
Aptar Digital Health today announced survey findings showcasing the impact of its iPump connected assistant for medication adherence. The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week. iPump, developed in conjunction with […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Medtronic reports first real-world data on smart insulin pen system
Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination. The data evaluated Medtronic’s Smart MDI system, which combines the InPen with the Simplera continuous glucose monitor (CGM). Data showed how the system, designed for people with diabetes using multiple daily injections (MDI) when used as intended, […]
Insulet study shows improvements with Omnipod 5 transitioning from multiple daily injections
Insulet (Nasdaq:PODD) today announced new Omnipod 5 clinical data highlighting the transition from multiple daily injections (MDI). Investigators shared data from the RADIANT study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. The randomized controlled trial evaluated the direct transition from MDI to automated insulin delivery (AID). Insulet […]
Tandem has positive data for automated insulin delivery in type 2 diabetes population
Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for type 2 diabetes. San Diego-based Tandem won FDA clearance for its Control-IQ+ next-generation algorithm for type 2 diabetes at the end of last month. Just yesterday, the company announced the launch of the algorithm. Control-IQ+ represents the next generation of the […]
